

SEDBASE: Side Effects of Drugs

FILE DESCRIPTION

SEDBASE: Side Effects of Drugs is a fulltext database that critically analyzes the published drug side effect literature on drugs currently in use. SEDBASE: Side Effects of Drugs acts as a quality filter since its drug class chapters are prepared by recognized authorities who critically assess and distill the published journal literature each year. The goal of the database is to document every drug known to have a side effect reported in the literature.

SEDBASE: Side Effects of Drugs is organized by drug class chapters and does not contain any speculative or unsubstantiated statements. Each year approximately 9,000 articles on adverse drug reactions are published in the scientific literature. These articles are sent to recognized authorities who critically assess the information and distill the key elements for inclusion in the database. Some of the specific areas covered include: adverse drug reactions, drug interactions, drug toxicity, special risk situations, and pharmacological or patient-dependent factors associated with the occurrence of side effects.

SUBJECT COVERAGE

- Adverse Drug Reactions
- Drug Interactions
- Drug Toxicity
- Pharmacological or Patient-Dependent Factors
Associated with the Occurrence of Side Effects
- Special Risk Situations

SOURCES

SEDBASE contains current, full-text information from the last 12 years of *Meyler's Side Effects of Drugs*, published every 4 years; *Side Effects of Drugs Annual*, published every year in between; and *Marler's Pharmacological & Chemical Synonyms*. SEDBASE also contains citations and abstracts from EMBASE (Files 72, 73) that have been referenced by the Meyler's texts.

DIALOG FILE DATA

Inclusive Dates: 1996-1997
Update Frequency: Closed
File Size: 85,777 records as of December 1997

CONTACT

SEDBASE is produced by Elsevier. Questions concerning file content should be directed to:
Elsevier B.V.
P.O. Box 211
Amsterdam, 1000 AE
The Netherlands
Phone: +31-20-4853-507
Fax: +31-20-4853-432
E-Mail: ebd-marketing@elsevier.com

SAMPLE RECORD

File 70:SEDBASE 1996/Jan Q1
(c) 1996 Elsevier B.V.

00728276 SEDBASE No.: 00109766 Line Count: 12

NR= Number of Cited Reference: 2
/DE, /NA, NA= Drug Name: LITHIUM
DC= Drug Classification: 03
/DE, SY= Synonym(s) for Drug Name: LITHIUM SALT; LITHIUM COMPOUND;
 LITHIUM CHLORIDE; LITHIUM CITRATE; LITHIUM CARBONATE
/DE, /IN, IN= Interacting Drug Name: METHYLDOPA
IC= Interacting Drug Classification Code: 21.04
 Synonym(s) for Interacting Drug: alpha methyl dopa;
 (-)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropionic acid;
 3,4-dihydroxy-alpha-methylphenylalanine;
 (-)-3-(3,4-dihydroxyphenyl)-2-methylalanine; MK-351; aldomet
 ; aldometil;
 2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropionic acid;
 3-(3,4-dihydroxyphenyl)-2-methylalanine; dopamet; dopegyt;
 hyperpax; medomet; mulfasin; presinol; sedometil;
 sembrina; hydromet

/DE, /EN, EN= Effect Interaction Name: SPEECH SLURRING
EC= Effect Classification Code: 14.03
/DE, /EN, EN= Synonym(s) for Effect Name: DYSARTHRIA
/DE, /FI, FI= FACTORS OF INFLUENCE: RENOVASCULAR HYPERTENSION
 OTHER FACTORS:

SP= Incidence mentioned

SO= Meyler's Side Effect of Drugs SED text, 03.08

/TX Problems can arise in antihypertensive treatment.
 One patient on lithium developed ataxia and slurred speech 2-3 weeks after starting methyl dopa. Serum lithium was 1.5 mmol/l 2 days after admission, and mild lithium intoxication might account for the symptoms. It is not clear whether the intoxication was precipitated by methyl dopa or by other factors in the presence of hypertensive renal insufficiency. It has been suggested that lithium patients needing antihypertensive drugs should preferably be given a beta-blocker, therapy with thiazides is inadvisable; amiloride may be less dangerous. Interaction with ACE inhibitors (inhibitors of the enzyme that converts angiotensin I to angiotensin II) such as enalapril, captopril, and lisinopril may lead to impaired glomerular filtration and elevation of serum creatine and serum lithium.

CITED REFERENCE(S):

/TI Title: Adverse interaction of lithium carbonate and methyl dopa.

AU= Author: O Regan J B.

CS= Author Address: 803 CN Towers, Saskatoon; Canada.

JN=, PY= Cited Works: CAN-MED-ASS-J 1976, 115/5 (385-386).

Cited Publication Year: 1976

LA= Language: English

/TI Title: The problem of antihypertensive treatment in lithium patients.

AU= Author: Schwarcz G.

CS= Author Address: St. Elizabeth Hosp., Washington, DC; USA.

JN=, PY= Cited Works: COMPR-PSYCHIATRY 1982, 23/1 (50-54).

Cited Publication Year: 1982

LA= Language: English

Country of Author: US.

/AB EMBASE Abstract: Given a thorough understanding of their pharmacology and of renal physiology, diuretics can usually be safely used in conjunction with lithium. Where possible, however, beta-blockers should be first-line drugs in treating hypertension since they have no electrolyte effects. Alternate drugs and checking for noncompliance can be useful in the hypertensive patient in whom first-line drugs are ineffective or contraindicated. Meyler's Side Effects of Drugs SED text, 03.08

SEARCH OPTIONS

BASIC INDEX

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	—	All Basic Index Fields	Word	S LITHIUM(W)CARBONATE
/AB	AB	Abstract	Word	S BETA(W)BLOCKER?/AB
/DE	DE	Descriptor ^{1,2}	Word & Phrase	S DYSARTHRIA/DE S RENOVASCULAR HYPERTENSION/DE
/EN	EN	Effect Interaction Name ³	Word & Phrase	S SPEECH/EN S SPEECH SLURRING/EN
/FI	FI	Factors of Influence ³	Word & Phrase	S HYPERTENSION/FI S RENAL INSUFFICIENCY/FI
/IN	IN	Interacting Drug Name ^{3,4}	Word & Phrase	S METHYLDOPA/IN S SODIUM BICARBONATE/IN
/NA	NA	Drug Name ⁴	Word & Phrase	S LITHIUM/NA S LOXAPINE SUCCINATE/NA
/TI	TI	Title of Cited Reference	Word	S LITHIUM(W)CARBONATE/TI
/TX	TX	Text	Word	S SERUM(W)LITHIUM/TX

¹ Also /DF.

⁴ Searchable in the Basic Index and in the Additional Indexes.

² Descriptor includes Drug Name, Interacting Drug Name, Effect Interaction Name, Factors of Influence, Synonyms (for Effect Name).

³ Also searchable using /DE.

ADDITIONAL INDEXES

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	AN	DIALOG Accession Number		
AN=	AN	SEDBASE Accession Number	Phrase	S AN=00109766
AU=	AU	Author Name	Phrase	S AU=O REGAN J B.
CS=	CS	Corporate Source	Word	S CS=(CN(W)TOWERS AND SASKATOON)
DC=	DC	Drug Classification Code	Phrase	S DC=03
EC=	EC	Effect Classification Code	Phrase	S EC=14.03
ED=	ED	Editor of Cited Book	Phrase	S ED=BOURNE P
EN=	EN	Effect Interaction Name ⁴	Phrase	S EN=SPEECH SLURRING
FI=	FI	Factors of Influence ⁴	Phrase	S FI=RENAL INSUFFICIENCY
IC=	IC	Interacting Drug Classification Code	Phrase	S IC=21.04
IN=	IN	Interacting Drug Name ^{3,4}	Phrase	S IN=METHYLDOPA
JN=	JN	Journal Name	Phrase	S JN=CAN-MED-ASS-J
LA=	LA	Language	Phrase	S LA=ENGLISH
—	LC	Number of Lines in Fulltext		
NA=	NA	Drug Name ⁴	Phrase	S NA=LITHIUM
NR=	NR	Number of Cited References	Phrase	S NR=2
PU=	PU	Publisher	Phrase	S PU=ELSEVIER, BIOMEDICAL PRESS?
PY=	PY	Publication Year	Phrase	S PY=1982
SO=	SO	Source Information	Phrase	S SO=MEYLER'S SIDE EFFECT OF DRUGS?
SP=	SP	Treatment, Incidence, Mechanism	Phrase	S SP=INCIDENCE MENTIONED
ST=	ST	Status	Phrase	S ST=NEW RECORD
SY=	SY	Synonyms for Drug Name and Interacting Drug Name	Phrase	S SY=LITHIUM SALT?
UD=	—	Update	Phrase	S UD=9999
XR=	XR	Cross Reference Field	Phrase	S XR=MAPROTILINE

SPECIAL FEATURES

For command descriptions, enter HELP LIMIT, HELP SORT, HELP RANK, HELP MAP online.

LIMIT	/INTERACT -- Interacting Drug Name Present /REF -- Cited References Present /YYYY -- Publication Year	S S1/INTERACT S S3/REF S S2/1993:1994
SORT	DC, EC, EN, IC, IN, NA	SORT S1/ALL/NA SORT S2/ALL/DC
RANK	All phrase- and numeric-indexed fields in the Additional Indexes can be ranked. Other RANK codes include: DE	RANK AU S3
MAP	NA, SY	MAP SY TEMP S1

PREDEFINED FORMAT OPTIONS

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG and SEDBASE Accession Numbers
2	--	Full Record except Text, EMBASE Abstract, and Cited Reference
3	Medium	Drug Name, Interacting Drug Name, Effect Interaction Name, Synonyms for Effect Name, Synonyms for Drug Name, Synonyms for Interactions
4	--	Full Record with Tagged Fields
5	Long	Full Record
6	Free	Drug Name, Number of Cited References, Effect Name, and Interacting Drug Name
7	--	Full Record except Indexing
8	Short	Drug Name, Number of Cited References, Effect Name, Interacting Drug Name, and Indexing
9	Full	Full Record
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

OTHER OUTPUT OPTIONS

For an explanation, enter HELP TYPE, HELP UDF, HELP TAG online.

USER DEFINED FORMATS	User-defined formats may be specified using the display codes indicated in the Search Options tables.	TYPE S3/NA,SY/1-5 PRINT S1/TI,AB/ALL
TAG	TAG may be used for tagged fields.	TYPE S2/9/1-5 TAG PRINT S1/5/ALL TAG DISPLAY S3/7/ALL TAG
DIRECT RECORD ACCESS	DIALOG Accession Number	TYPE 0001685/5 DISPLAY 0001443/9 PRINT 0001562/3

FOR ONLINE HELP:

See HELP FIELDS 70 for searchable fields; HELP FORMAT 70 for output formats; HELP LIMIT 70 for limits; HELP RATES 70 for cost information; HELP SORT 70 for sorts.